Funded Startups in Saint Louis
Across the 24 most recent Saint Louis–listed rounds, Geneoscopy’s $105M Series C on 2025-01-08 stands out as the only disclosed amount above $50M; the next…
Across the 24 most recent Saint Louis–listed rounds, Geneoscopy’s $105M Series C on 2025-01-08 stands out as the only disclosed amount above $50M; the next-largest disclosed figures cluster far lower, including Capacity at $26M (2024-10-16), SimpleRose at $23M (2023-04-06), and Battle Financial at $15M (2024-04-10). Disclosed amounts also show a floor: the smallest disclosed round is Engagedly’s $100K private equity on 2022-02-23.
The list spans 2020-08-01 (TCARE, Community and Lifestyle) through 2025-10-14 (EIWA, Agriculture and Farming), with a concentration in the most recent window: four rounds with disclosed amounts land in 2024 (Capacity $26M on 2024-10-16; Battle Financial $15M on 2024-04-10; plus two additional disclosed entries in early/mid-2024). Stage and disclosure are mixed: 12 of 24 rows are labeled “Series Unknown” and 3 of 24 are “undisclosed,” while a visible sector cluster appears in Biotechnology (four entries: Geneoscopy, Pluton Biosciences, C2N Diagnostics, and Kypha).
Most recent rounds
24 shownRelated listings
Frequently asked
What’s the largest disclosed round in the Saint Louis list, and how extreme is it versus the rest?
Geneoscopy’s $105M disclosed Series C on 2025-01-08 is the only amount above $50M in these 24 rows. The next-largest disclosed amounts are $26M (Capacity on 2024-10-16), $23M (SimpleRose on 2023-04-06), and $17M (Pluton Biosciences on 2023-05-24), placing the top round in a distinctly higher range.
Do recent rounds cluster in time, or are they evenly spread across the 2020–2025 range?
They skew toward the recent end of the window: at least one disclosed round appears every year shown from 2022 onward (e.g., Flipstik $1M on 2022-12-19, Kypha $5M on 2022-05-12, and Capacity $26M on 2024-10-16). The overall span runs from 2020-08-01 (TCARE) to 2025-10-14 (EIWA), but multiple notable disclosed rounds occur within the last 12 months of 2024–2025 (e.g., Geneoscopy $105M in 2025 and Capacity $26M in late 2024).
Which disclosure/stage categories dominate, and does that limit what analysts can compare?
“Series Unknown” appears on 12 of 24 rows, and “undisclosed” appears on 3 of 24, so 15 of 24 entries do not provide a comparable disclosed amount plus a clear stage label. Examples include ATIS (2024-09-24, undisclosed) and CERV (2025-04-23, undisclosed), alongside other rounds where the stage is “Series Unknown” such as Atomation (2025-05-12, $2M).
Is any sector over-represented, based on repeated categories in the rows shown?
Biotechnology is the clearest repeated sector, appearing four times: Geneoscopy (2025-01-08, $105M), Pluton Biosciences (2023-05-24, $17M), C2N Diagnostics (2023-02-16, $15M), and Kypha (2022-05-12, $5M). Other sectors (e.g., Financial Services with Battle Financial at $15M on 2024-04-10 and SwipeSum at $3M on 2022-06-03) appear fewer times.
Are there notable outliers on the low end of disclosed amounts, and where do they sit relative to larger rounds?
The smallest disclosed amount is Engagedly at $100K on 2022-02-23 (Private Equity), which is far below the rest of the disclosed amounts listed. Even within the “lower double-digit millions” band, examples like Battle Financial’s $15M (2024-04-10) and C2N Diagnostics’s $15M (2023-02-16) dwarf the $100K round.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.